A Phase IB Dose Exploration Trial With MK-8628, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Subjects With Selected Advanced Solid Tumors

Trial Profile

A Phase IB Dose Exploration Trial With MK-8628, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Subjects With Selected Advanced Solid Tumors

Discontinued
Phase of Trial: Phase I

Latest Information Update: 07 Aug 2017

At a glance

  • Drugs Birabresib (Primary)
  • Indications Breast cancer; Non-small cell lung cancer; Prostate cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Merck Sharp & Dohme; OncoEthix
  • Most Recent Events

    • 04 Aug 2017 This trial has been completed in Belgium (end date: 26 Apr 2017).
    • 23 May 2017 Status changed from completed to discontinued.
    • 10 May 2017 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top